AIP
JANX icon

Ameritas Investment Partners’s Janux Therapeutics JANX Stock Holding History

Ameritas Investment Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.7K Hold
3,289
– – ﹤0.01% 2138
2025
Q4 		$45.4K Hold
3,289
– – ﹤0.01% 2200
2025
Q3 		$80.4K Sell
3,289
-731
-18% -$17.8K ﹤0.01% 1822
2025
Q2 		$92.9K Buy
4,020
+820
+26% +$21.6K ﹤0.01% 1809
2025
Q1 		$86.4K Buy
3,200
+453
+16% +$17.1K ﹤0.01% 1803
2024
Q4 		$147K Hold
2,747
– – ﹤0.01% 1517
2024
Q3 		$125K Hold
2,747
– – ﹤0.01% 1650
2024
Q2 		$115K Buy
2,747
+1,041
+61% +$48.9K ﹤0.01% 1635
2024
Q1 		$64.2K Hold
1,706
– – ﹤0.01% 2003
2023
Q4 		$18.3K Hold
1,706
– – ﹤0.01% 2614
2023
Q3 		$17.2K Buy
1,706
+692
+68% +$7.98K ﹤0.01% 2607
2023
Q2 		$12K Hold
1,014
– – ﹤0.01% 2840
2023
Q1 		$12.3K Hold
1,014
– – ﹤0.01% 2654
2022
Q4 		$20.8K Hold
1,014
– – ﹤0.01% 2549
2022
Q3 		$13K Hold
1,014
– – ﹤0.01% 2709
2022
Q2 		$12K Hold
1,014
– – ﹤0.01% 2783
2022
Q1 		$15K Hold
1,014
– – ﹤0.01% 2665
2021
Q4 		$20K Hold
1,014
– – ﹤0.01% 2647
2021
Q3 		$22K Buy
+1,014
New +$29.2K ﹤0.01% 2648

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameritas Investment Partners's JANX Position: Q1 2026 in Review

Ameritas Investment Partners held its Janux Therapeutics (JANX) position steady in Q1 2026 at 3,289 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Ameritas Investment Partners first reported a position in JANX in Q3 2021 and has held it in 19 quarters since. The position peaked at $147K in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Ameritas Investment Partners held 3,289 shares of Janux Therapeutics worth $45.7K as of Q1 2026.
  • Ameritas Investment Partners left its Janux Therapeutics share count unchanged in Q1 2026.
  • Janux Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2138 holding.
  • Ameritas Investment Partners first reported a position in Janux Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Ameritas Investment Partners's Janux Therapeutics position peaked at $147K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.